Original-Research: CLINUVEL Pharmaceuticals Limited (von Parmantier & Cie. Gm...

Original-Research: CLINUVEL Pharmaceuticals Limited - from Parmantier & Cie.

boerse.de-Aktien-Ausblick:
Wie es an den Börsen jetzt weitergeht!
Hier gratis anfordern ...

GmbH

30.09.2025 / 10:52 CET/CEST

Dissemination of a Research, transmitted by EQS News - a service of EQS

Group.

The issuer is solely responsible for the content of this research. The

result of this research does not constitute investment advice or an

invitation to conclude certain stock exchange transactions.

Classification of Parmantier & Cie. GmbH to CLINUVEL Pharmaceuticals Limited

Company Name: CLINUVEL Pharmaceuticals Limited

ISIN: AU000000CUV3

Reason for the research: Update

Recommendation: Buy

from: 30.09.2025

Target price: 26.50 AU$

Target price on sight of: 12 month

Last rating change: none

Analyst: Thomas Schiessle, Daniel Großjohann

CLINUVEL strengthens global position with tariff advantage and Nasdaq

uplisting

Frankfurt am Main, 30 September 2025. Parmantier & Cie highlights in its

latest research note the strategic decisions taken by CLINUVEL

Pharmaceuticals Limited (ASX: CUV; Nasdaq ADR: CLVLY), combining operational

resilience with a clear capital markets strategy. The company is positioning

itself strongly for its next phase of growth.

A key element of CLINUVEL's strategy is its effective protection against

potential trade barriers in the United States. While many international

pharma and biotech companies are facing the impact of looming import

tariffs, CLINUVEL remains largely unaffected thanks to its forward-looking

production and logistics setup. By expanding its own manufacturing

capacities in the US, the company has effectively shielded itself from

potential 100% import tariffs. This tariff resilience not only safeguards

margins and supply chains but also provides a clear competitive advantage in

an increasingly protectionist environment.

At the same time, CLINUVEL is advancing the internationalisation of its

capital markets presence. By the end of 2025, the company plans to upgrade

its American Depositary Receipt (ADR) programme from Level I to Level II on

the Nasdaq. This move will meet the more demanding regulatory requirements

of US capital markets and open the door to new investor groups, particularly

institutional investors in North America. With more than 250 listed

companies and a market capitalisation of approximately USD 1.22 trillion,

the Nasdaq Biotechnology Index (NBI) is the world's leading marketplace for

biotech firms. Uplisting to Level II will significantly increase CLINUVEL's

visibility in the US and broaden its investor base - without the need for a

capital increase.

The timing of this step is well chosen. The ongoing interest rate cuts by

the US Federal Reserve are creating a supportive environment for equity

markets, particularly for biotech stocks. CLINUVEL is taking advantage of

this momentum to strengthen its presence in the US capital markets and to

further implement its global growth strategy, while maintaining its primary

listing on the Australian Securities Exchange (ASX).

By combining operational robustness against tariff risks with the upcoming

Nasdaq uplisting, CLINUVEL is sending a clear strategic signal. The company

is uniting stability with expansion potential, laying the foundation for

sustainable international growth.

Full research report available at:

Bloomberg ; FactSet ; LSEG

Online: https://www.parmantiercie.com/research

About PARMANTIER & CIE. GmbH

PARMANTIER & CIE. is a modern merchant bank based in Frankfurt am Main. The

firm advises companies on all aspects of financing - equity, debt, and

hybrid instruments - and also invests its own capital in listed and private

companies. PARMANTIER & CIE. stands for integrity, foresight, and tailored

financing solutions with entrepreneurial commitment.

You can download the research here:

https://eqs-cockpit.com/c/fncls.ssp?u=219fe91c1d9596a5c938b7af2a1d8a22

Contact for questions:

Parmantier & Cie. Research

Hungener Straße 6

60389 Frankfurt am Main

E-mail: [email protected]

The EQS Distribution Services include Regulatory Announcements,

Financial/Corporate News and Press Releases.

Archive at www.eqs-news.com

2205916 30.09.2025 CET/CEST

°

Quelle: dpa-AFX